S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?

Cytokinetics (CYTK) Stock Price, News & Analysis

$73.09
-7.90 (-9.75%)
(As of 02/28/2024 ET)
Today's Range
$69.47
$78.60
50-Day Range
$44.60
$108.06
52-Week Range
$25.98
$110.25
Volume
4.38 million shs
Average Volume
3.73 million shs
Market Capitalization
$7.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.94

Cytokinetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
1.2% Upside
$73.94 Price Target
Short Interest
Bearish
14.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
0.13mentions of Cytokinetics in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$8.57 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.94) to ($4.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.99 out of 5 stars

Medical Sector

410th out of 958 stocks

Pharmaceutical Preparations Industry

175th out of 416 stocks


CYTK stock logo

About Cytokinetics Stock (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Stock Price History

CYTK Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Cytokinetics CEO: No ongoing sale process
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Cytokinetics Reports Fourth Quarter 2023 Financial Results
Cytokinetics Q4 2023 Earnings Preview
CYTK Mar 2024 95.000 call
CYTK Mar 2024 79.500 put
CYTK Mar 2024 79.000 put
CYTK Mar 2024 125.000 call
CYTK Feb 2024 84.000 call
Cytokinetics (CYTK) Scheduled to Post Quarterly Earnings on Tuesday
CYTK Feb 2024 72.000 put
CYTK Feb 2024 85.500 call
CYTK Feb 2024 80.500 put
CYTK Feb 2024 86.000 call
CYTK Feb 2024 83.000 put
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
2/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTK
Employees
409
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$73.94
High Stock Price Target
$108.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+1.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-388,950,000.00
Net Margins
-6,736.12%
Pretax Margin
-6,739.96%

Debt

Sales & Book Value

Annual Sales
$94.59 million
Book Value
($1.14) per share

Miscellaneous

Free Float
94,328,000
Market Cap
$7.17 billion
Optionable
Optionable
Beta
0.73

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives















CYTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price target for 2024?

15 Wall Street research analysts have issued 1-year price targets for Cytokinetics' stock. Their CYTK share price targets range from $42.00 to $108.00. On average, they predict the company's stock price to reach $73.94 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2024?

Cytokinetics' stock was trading at $83.49 at the beginning of the year. Since then, CYTK stock has decreased by 12.5% and is now trading at $73.09.
View the best growth stocks for 2024 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.03) by $0.35. The biopharmaceutical company earned $1.70 million during the quarter, compared to analyst estimates of $7.62 million. The company's revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.45) earnings per share.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.24%), Price T Rowe Associates Inc. MD (3.31%), RTW Investments LP (2.58%), Northern Trust Corp (1.08%), First Turn Management LLC (0.82%) and Charles Schwab Investment Management Inc. (0.81%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTK) was last updated on 2/29/2024 by MarketBeat.com Staff